Insider Buying: NeuroSense Therapeutics (NASDAQ:NRSN) CEO Acquires $200,000.00 in Stock

NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) CEO Alon Ben-Noon bought 250,000 shares of the business’s stock in a transaction on Tuesday, June 16th. The shares were acquired at an average price of $0.80 per share, with a total value of $200,000.00. Following the completion of the purchase, the chief executive officer directly owned 4,534,233 shares of the company’s stock, valued at approximately $3,627,386.40. The trade was a 5.84% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink.

NeuroSense Therapeutics Stock Performance

Shares of NRSN opened at $0.80 on Friday. NeuroSense Therapeutics Ltd. has a 52-week low of $0.63 and a 52-week high of $2.52. The business’s fifty day moving average is $0.78 and its 200-day moving average is $0.85. The firm has a market cap of $26.20 million, a price-to-earnings ratio of -1.49 and a beta of 1.56.

Wall Street Analysts Forecast Growth

Several brokerages have commented on NRSN. Weiss Ratings reissued a “sell (d-)” rating on shares of NeuroSense Therapeutics in a research note on Friday, May 8th. D. Boral Capital reiterated a “buy” rating and set a $14.00 price objective on shares of NeuroSense Therapeutics in a research report on Wednesday, April 8th. Finally, Roth Mkm initiated coverage on shares of NeuroSense Therapeutics in a research note on Tuesday, March 10th. They issued a “buy” rating and a $3.00 price objective for the company. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $8.50.

Hedge Funds Weigh In On NeuroSense Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Yorkville Advisors Global LP bought a new stake in NeuroSense Therapeutics in the fourth quarter valued at approximately $77,000. Squarepoint Ops LLC raised its holdings in NeuroSense Therapeutics by 91.0% during the 3rd quarter. Squarepoint Ops LLC now owns 95,375 shares of the company’s stock worth $119,000 after purchasing an additional 45,450 shares during the last quarter. Jane Street Group LLC bought a new position in NeuroSense Therapeutics during the 2nd quarter worth approximately $54,000. Finally, Two Sigma Investments LP acquired a new position in shares of NeuroSense Therapeutics in the 3rd quarter worth approximately $26,000. 1.04% of the stock is owned by institutional investors and hedge funds.

NeuroSense Therapeutics Company Profile

NeuroSense Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for neurodegenerative and age-related neurological disorders. The company’s primary mission is to address unmet medical needs in diseases characterized by protein aggregation, chronic inflammation and cellular senescence in the central nervous system.

At the core of NeuroSense’s approach is a proprietary senotherapeutic platform designed to selectively target and clear senescent cells that contribute to neurodegeneration.